Catalent, Inc., operating globally through its various subsidiaries, specializes in the development and production of comprehensive solutions for a wide array of products, including pharmaceutical drugs, protein-based biologics, advanced cell and gene therapies, and consumer health items. The company's operations are strategically divided into four key segments: Biologics; Softgel and Oral Technologies; Oral and Specialty Delivery; and Clinical Supply Services. The Softgel and Oral Technologies division focuses on the formulation, development, and manufacturing of soft capsules. These are utilized in a diverse range of client products, such as prescription medications, over-the-counter drugs, nutritional supplements, unit-dose cosmetics, and medicinal preparations for animal health. Within the Biologics segment, Catalent undertakes the creation of biologic cell lines, develops and manufactures both cell therapy and viral-based gene therapy, and handles the formulation and production of parenteral dose forms, including vials, prefilled syringes, and cartridges. This segment also provides essential analytical development and testing capabilities. The Oral and Specialty Delivery segment offers extensive formulation, development, and manufacturing expertise across various technologies. It provides integrated downstream solutions spanning clinical development and commercial supply. This segment also features a dedicated oral delivery solutions platform, encompassing preclinical screening, formulation, analytical development, and current good manufacturing practices (cGMP) services. Finally, the Clinical Supply Services segment delivers vital support for drug and biologic clinical trials. Its services include manufacturing, specialized packaging, secure storage, efficient distribution, and comprehensive inventory management. This segment also offers "FastChain," a demand-led clinical supply service. Catalent serves a broad client base, including pharmaceutical, biotechnology, and consumer health organizations, alongside companies in other healthcare sectors like animal health and medical devices, and even the cosmetics industry. The company was founded in 2007 and maintains its headquarters in Somerset, New Jersey.
Track Record
Showing latest 4 periods • Swipe for more
Metric
2015
2014
2013
2012
2011
Revenue
1.83B
1.83B
1.80B
1.69B
1.53B
Net Income
212.20M
16.20M
(46.70M)
(24.40M)
(54.00M)
EPS
1.77
0.14
-0.40
-0.21
-0.46
Free Cash Flow
30.80M
55.90M
15.20M
(16.30M)
12.40M
FCF / Share
0.26
0.48
0.13
-0.14
0.11
Operating CF
171.80M
178.30M
137.70M
87.90M
99.70M
Total Assets
3.15B
3.09B
3.06B
3.14B
N/A
Total Debt
1.89B
2.71B
2.69B
2.68B
N/A
Cash & Equiv
151.30M
74.40M
106.40M
139.00M
N/A
Book Value
634.00M
(371.80M)
(410.70M)
(350.70M)
N/A
Return on Equity
0.33
N/A
N/A
N/A
N/A
Metric
Q1 2025
Q4 2015
Q3 2015
Q2 2015
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014
Q4 2013
Q3 2013
Q2 2013
Revenue
1.02B
510.10M
446.60M
455.80M
418.30M
519.60M
453.10M
440.70M
414.30M
505.20M
447.00M
436.10M
Net Income
(129.00M)
153.70M
31.50M
46.50M
(19.50M)
27.20M
6.70M
(19.20M)
1.50M
19.20M
(18.80M)
(27.40M)
EPS
-0.71
1.23
0.25
0.37
-0.19
0.23
0.06
-0.16
0.01
0.16
-0.16
-0.23
Free Cash Flow
4.00M
44.80M
56.90M
100,000
(71.00M)
24.60M
30.70M
(5.80M)
6.40M
16.80M
25.50M
(14.60M)
FCF / Share
0.02
0.36
0.46
0.00
-0.68
0.21
0.26
-0.05
0.05
0.14
0.22
-0.12
Operating CF
61.00M
77.10M
94.30M
40.20M
(39.80M)
85.00M
52.90M
15.20M
25.20M
54.50M
57.50M
13.60M
Total Assets
9.71B
3.15B
2.97B
3.04B
2.95B
3.09B
3.09B
3.07B
3.04B
3.06B
N/A
N/A
Total Debt
4.95B
1.89B
1.88B
1.93B
1.82B
2.71B
2.70B
2.73B
2.70B
2.69B
N/A
N/A
Cash & Equiv
335.00M
151.30M
116.10M
84.10M
63.20M
74.40M
55.70M
64.20M
95.80M
106.40M
N/A
N/A
Book Value
3.54B
634.00M
468.20M
492.40M
503.00M
(371.80M)
(400.00M)
(414.10M)
(386.90M)
(410.70M)
N/A
N/A
Return on Equity
-0.04
0.24
0.07
0.09
-0.04
N/A
N/A
N/A
N/A
N/A
N/A
N/A
CTLT News
No news available for CTLT.
Log out?
You will be signed out of AlphaMadera on this device.